Innovent Biologics Inc Cash Flow-to-Debt Ratio
Innovent Biologics Inc cash flow-to-debt ratio. Innovent Biologics Inc (6IB) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2023, meaning its operating cash flow of €-311.45 Million could theoretically repay 0% of its total liabilities (€7.11 Billion) in one year. Check Innovent Biologics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Innovent Biologics Inc (2016–2025)
Cash flow-to-debt ratio of Innovent Biologics Inc from 2016 to 2025. Historical debt coverage capacity for Innovent Biologics Inc across 10 annual periods. Check Innovent Biologics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Innovent Biologics Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Innovent Biologics Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Innovent Biologics Inc. For the full cash flow conversion analysis, see Innovent Biologics Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.56x | €10.00 Billion | €17.99 Billion | ▲ +266.5% |
| 2024 | 0.15x | €1.29 Billion | €8.48 Billion | ▲ +731.2% |
| 2023 | 0.02x | €147.81 Million | €8.10 Billion | ▲ +106.5% |
| 2022 | -0.28x | €-1.92 Billion | €6.86 Billion | ▲ +18.3% |
| 2021 | -0.34x | €-2.02 Billion | €5.91 Billion | ▼ -240.0% |
| 2020 | -0.10x | €-307.69 Million | €3.06 Billion | ▲ +85.0% |
| 2019 | -0.67x | €-1.66 Billion | €2.47 Billion | ▼ -27.5% |
| 2018 | -0.53x | €-1.01 Billion | €1.92 Billion | ▼ -337.1% |
| 2017 | -0.12x | €-492.27 Million | €4.08 Billion | ▼ -25.5% |
| 2016 | -0.10x | €-362.99 Million | €3.77 Billion | — |